1. Mund JA, Shannon H, Sinn AL, Cai S, Wang H, Pradhan KR, et al. Human proangiogenic circulating hematopoietic stem and progenitor cells promote tumor growth in an orthotopic melanoma xenograft model. Angiogenesis 2013; 16:953–962.
2. Melo SA, Kalluri R. Angiogenesis is controlled by miR-27b associated with endothelial tip cells. Blood 2012; 119:2439–2440.
3. Li WW, Li VW, Hutnik M, Chiou AS. Tumor angiogenesis as a target for dietary cancer prevention. J Oncol 2012; 2012:879623.
4. Zarfeshany A, Asgary S, Javanmard SH. Potent health effects of pomegranate. Adv Biomed Res 2014; 3:100.
5. Yasoubi M, Barzegar MA, Sahari MHA. Total phenolic contents and antioxidant activity of Pomegranate (Punica granatum L.) Peel Extracts. J Agric Sci Technol 2007;9:35–42.
6. Dana N, Haghjooy Javanmard Sh RL. Inhibition of vascular endothelial growth factor-induced angiogenesis by black Pomegranate peel extract and antiproliferative effect in melanoma cell line. Res Pharm Sci 2015; 10:117-124.
7. Jeune MAL, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food 2005; 8:469–475.
8. Khan GN, Gorin MA, Rosenthal D, Pan Q, Bao LW, Wu ZF, et al. Pomegranate fruit extract impairs invasion and motility in human breast cancer. Integr Cancer Ther 2009; 8:242–253.
9. Jurenka JS. Therapeutic applications of pomegra-nate (Punica granatum L.): a review. Altern Med Rev 2008; 13:128–144.
10. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 2008; 32:475–480.
11. Huang THW, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, et al. Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component. Toxicol Appl Pharmacol 2005; 207:160–169.
12. Hontecillas R, O’Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J Am Coll Nutr 2009; 28:184–195.
13. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011; 2:236–240.
14. Woo CC, Loo SY, Gee V, Yap CW, Sethi G, Kumar AP, et al. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway. Biochem Pharmacol 2011; 82:464–475.
15. Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G FA. Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis 2009; 19:751–759.
16. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53:409–435.
17. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878–1886.
18. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15–24.
19. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2015; 277:19649–19657.
20. Ding L, Liang X-G, Lou Y-J. Time-dependence of cardiomyocyte differentiation disturbed by peroxisome proliferator-activated receptor alpha inhibitor GW6471 in murine embryonic stem cells in vitro. Acta Pharmacol Sin 2015; 28:634–642.
21. Giusti MM, Rodríguez-Saona LE, Wrolstad RE. Molar absorptivity and color characteristics of acylated and non-acylated pelargonidin-based anthocyanins. J Agric Food Chem 1999; 47:4631–4637.
22. Jeganathan NS KK. HPTLC method for estimation of ellagic acid and gallic acid in Triphala churanam formulations. Res J Phytochem 2008; 2:1–9.
23. Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesi 2003; 6:121–128.
24.Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 1994; 269:9986–9992.
25. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marcé M, Losordo DW, et al. Comparative analysis of the in vivo angiogenic properties of stable
prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004; 36:363–370.
26. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274:9116–9121.
27. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999; 274:17042–17048.
28. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008; 57:1394–1404.
29. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnés CM, Fannon M, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105:985–990.
30. Varet J, Vincent L, Mirshahi P, Pille J V, Legrand E, Opolon P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 2003; 60:810–819.
31. Meissner M, Stein M, Urbich C, Reisinger K, Suske G, Staels B, et al. PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004; 94:324–332.
32. Dana N, Javanmard SH, Fazilati M, Pilehvarian AA. A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis. Adv Biomed Res 2013; 2:54.
33. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002; 40:748–754.
34. Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2004; 2:541–550.